Cyclacel announces publication of preclinical data on plogosertib
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 07 2025
0mins
Research Findings: A study published in the journal Gut reveals that the DNAJ-PKAc fusion oncoprotein increases sensitivity to PLK1 inhibitors, particularly plogosertib, in fibrolamellar carcinoma (FLC) by promoting mitotic progression and making FLC cells reliant on PLK1.
Treatment Implications: The findings suggest that plogosertib could be a promising treatment option for FLC, warranting further preclinical and clinical evaluations due to its effectiveness in reducing FLC growth while sparing normal liver cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
